Breast Cancer Stem Cells and Genotyping_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

HAN Mingli , WU Chengyi

Department of Endocrine Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China;

Corresponding author：

Keywords：

Breast cancer; Heterogeneity; Genotyping; Cancer stem cell

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the advancement of breast cancer stem cells and genotyping and analyze the correlation between the two.
Methods Relevant literatures about breast cancer stem cells and genotyping, which were published recently were collected and reviewed.
Results Cancer stem cell origin theory was supported by researches of correlation between breast cancer stem cells and genotyping, which also explained the complexity of intrinsic subtypes and heterogeneity of breast cancer.
Conclusions A new way can be detected to study the formation mechanism and biological characteristics of breast cancer at the cellular and molecular level by researches of correlation between breast cancer stem cells and genotyping, which are expected to provide new strategies and tools for diagnosis and treatment of breast cancer.

Citation： HAN Mingli,WU Chengyi. Breast Cancer Stem Cells and Genotyping. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2010, 17(3): 302-305. doi: Copy

1.	魏于全,　吴扬. 乳腺癌生物治疗进展 [J]. 中国普外基础与临床杂志, 2004; 11(1): 35.
2.	莫敖, 吴诚义. 肿瘤干细胞与实体肿瘤 [J]. 中国普外基础与临床杂志, 2007; 14(5): 612614.
3.	Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions [J]. Nat Rev Cancer, 2008; 8(10): 755768.
4.	AlHajj M, Wicha MS, BenitoHernandez A, et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci USA, 2003; 100(11): 39833988.
5.	Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties [J]. Cancer Res, 2005; 65(13): 55065511.
6.	Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis [J]. Breast Cancer Res, 2006; 8(5): R59.
7.	Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on [J]. Curr Stem Cell Res Ther, 2009; 4(1): 5060.
8.	Ginestier C, Hur MH, CharafeJauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [J]. Cell Stem Cell, 2007; 1(5): 555567.
9.	Patrawala L, Calhoun T, SchneiderBroussard R, et al. Side population is enriched in tumorigenic, stemlike cancer cells, whereas ABCG2+ and ABCG2－ cancer cells are similarly tumorigenic [J]. Cancer Res, 2005; 65(14): 62076219.
10.	Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breastcancer cells [J]. N Engl J Med, 2007; 356(3): 217226.
11.	Phillips TM, McBride WH, Pajonk F. The response of CD24－/low/CD44+ breast cancer－initiating cells to radiation [J]. J Natl Cancer Inst, 2006; 98(24): 17771785.
12.	Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis [J]. Clin Cancer Res, 2005; 11(3): 11541159.
13.	Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression [J]. Cancer Sci, 2009; 100(6): 10621068.
14.	Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature, 2000; 406(6797): 747752.
15.	Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/basallike breast carcinomas [J]. Breast Cancer Res, 2007; 9(5): R65.
16.	Lo SS, Norton J, Mumby PB, et al. Prospective multicenter study of the impact of the 21gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection [J]. J Clin Oncol, 2007; 25(18S): 577.
17.	Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J]. N Engl J Med, 2006; 354(20): 21032111.
18.	PiccartGebhart MJ, Procter M, LeylandJones B, et al. Trastuzumab after adjuvant chemotherapy in HER2positive breast cancer [J]. N Engl J Med, 2005; 353(16): 16591672.
19.	Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16): 53675374.
20.	Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA, 2001; 98(19): 1086910874.
21.	Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse [J]. Cancer Res, 2008; 68(9): 31083114.
22.	Honeth G, Bendahl PO, Ringnér M, et al. The CD44+/CD24- phenotype is enriched in basallike breast tumors [J]. Breast Cancer Res, 2008; 10(3): R53.
23.	Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes [J]. Cancer Cell, 2006; 10(6): 515527.
24.	Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells [J]. Cell, 2008; 133(4): 704715.
25.	Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity [J]. Cancer Cell, 2007; 11(3): 259273.
26.	Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion [J]. Oncogene, 2008; 27(47): 61206130.
27.	Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1 [J]. Cancer Res, 2008; 68(7): 24192426.
28.	Zhang M, Behbod F, Atkinson RL, et al. Identification of tumorinitiating cells in a p53null mouse model of breast cancer [J]. Cancer Res, 2008; 68(12): 46744682.
29.	Molyneux G, Regan J, Smalley MJ. Mammary stem cells and breast cancer [J]. Cell Mol Life Sci, 2007; 64(24): 32483260.
30.	Dontu G, ElAshry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor [J]. Trends Endocrinol Metab, 2004; 15(5): 193197.

1. 魏于全,　吴扬. 乳腺癌生物治疗进展 [J]. 中国普外基础与临床杂志, 2004; 11(1): 35.
2. 莫敖, 吴诚义. 肿瘤干细胞与实体肿瘤 [J]. 中国普外基础与临床杂志, 2007; 14(5): 612614.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions [J]. Nat Rev Cancer, 2008; 8(10): 755768.
4. AlHajj M, Wicha MS, BenitoHernandez A, et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci USA, 2003; 100(11): 39833988.
5. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties [J]. Cancer Res, 2005; 65(13): 55065511.
6. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis [J]. Breast Cancer Res, 2006; 8(5): R59.
7. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on [J]. Curr Stem Cell Res Ther, 2009; 4(1): 5060.
8. Ginestier C, Hur MH, CharafeJauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [J]. Cell Stem Cell, 2007; 1(5): 555567.
9. Patrawala L, Calhoun T, SchneiderBroussard R, et al. Side population is enriched in tumorigenic, stemlike cancer cells, whereas ABCG2+ and ABCG2－ cancer cells are similarly tumorigenic [J]. Cancer Res, 2005; 65(14): 62076219.
10. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breastcancer cells [J]. N Engl J Med, 2007; 356(3): 217226.
11. Phillips TM, McBride WH, Pajonk F. The response of CD24－/low/CD44+ breast cancer－initiating cells to radiation [J]. J Natl Cancer Inst, 2006; 98(24): 17771785.
12. Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis [J]. Clin Cancer Res, 2005; 11(3): 11541159.
13. Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression [J]. Cancer Sci, 2009; 100(6): 10621068.
14. Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature, 2000; 406(6797): 747752.
15. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/basallike breast carcinomas [J]. Breast Cancer Res, 2007; 9(5): R65.
16. Lo SS, Norton J, Mumby PB, et al. Prospective multicenter study of the impact of the 21gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection [J]. J Clin Oncol, 2007; 25(18S): 577.
17. Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J]. N Engl J Med, 2006; 354(20): 21032111.
18. PiccartGebhart MJ, Procter M, LeylandJones B, et al. Trastuzumab after adjuvant chemotherapy in HER2positive breast cancer [J]. N Engl J Med, 2005; 353(16): 16591672.
19. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16): 53675374.
20. Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA, 2001; 98(19): 1086910874.
21. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse [J]. Cancer Res, 2008; 68(9): 31083114.
22. Honeth G, Bendahl PO, Ringnér M, et al. The CD44+/CD24- phenotype is enriched in basallike breast tumors [J]. Breast Cancer Res, 2008; 10(3): R53.
23. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes [J]. Cancer Cell, 2006; 10(6): 515527.
24. Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells [J]. Cell, 2008; 133(4): 704715.
25. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity [J]. Cancer Cell, 2007; 11(3): 259273.
26. Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion [J]. Oncogene, 2008; 27(47): 61206130.
27. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1 [J]. Cancer Res, 2008; 68(7): 24192426.
28. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumorinitiating cells in a p53null mouse model of breast cancer [J]. Cancer Res, 2008; 68(12): 46744682.
29. Molyneux G, Regan J, Smalley MJ. Mammary stem cells and breast cancer [J]. Cell Mol Life Sci, 2007; 64(24): 32483260.
30. Dontu G, ElAshry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor [J]. Trends Endocrinol Metab, 2004; 15(5): 193197.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Breast Cancer Stem Cells and Genotyping

Abstract Full text Figures/Tables Video References Cited by

Format

Content